- Home
- CION vs ARVN Comparison
CION vs ARVN Comparison
Compare CION & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CION
- ARVN
- Stock Information
- Founded
- CION 2011
- ARVN 2015
- Country
- CION United States
- ARVN United States
- Employees
- CION N/A
- ARVN N/A
- Industry
- CION Finance/Investors Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CION Finance
- ARVN Health Care
- Exchange
- CION Nasdaq
- ARVN Nasdaq
- Market Cap
- CION 521.7M
- ARVN 456.2M
- IPO Year
- CION N/A
- ARVN 2018
- Fundamental
- Price
- CION $10.07
- ARVN $7.84
- Analyst Decision
- CION Sell
- ARVN Buy
- Analyst Count
- CION 2
- ARVN 21
- Target Price
- CION $11.00
- ARVN $20.53
- AVG Volume (30 Days)
- CION 242.9K
- ARVN 1.9M
- Earning Date
- CION 08-07-2025
- ARVN 08-05-2025
- Dividend Yield
- CION 14.31%
- ARVN N/A
- EPS Growth
- CION N/A
- ARVN N/A
- EPS
- CION N/A
- ARVN N/A
- Revenue
- CION $234,952,000.00
- ARVN $426,900,000.00
- Revenue This Year
- CION N/A
- ARVN $7.57
- Revenue Next Year
- CION N/A
- ARVN N/A
- P/E Ratio
- CION N/A
- ARVN N/A
- Revenue Growth
- CION N/A
- ARVN 498.74
- 52 Week Low
- CION $8.51
- ARVN $5.90
- 52 Week High
- CION $12.71
- ARVN $30.24
- Technical
- Relative Strength Index (RSI)
- CION 62.12
- ARVN 53.58
- Support Level
- CION $10.01
- ARVN $7.32
- Resistance Level
- CION $10.27
- ARVN $8.05
- Average True Range (ATR)
- CION 0.16
- ARVN 0.42
- MACD
- CION 0.02
- ARVN -0.00
- Stochastic Oscillator
- CION 69.70
- ARVN 52.53
About CION CION Investment Corporation
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.